GCG ((−)‐gallocatechin gallate) and EGCG ((−)‐epigallocatechin‐3‐gallate) are main biologically active polyphenolic compounds in tea leaves, and EGCG has been studied for its potential effects on alleviating diabetic nephropathy (DN). Previous studies showed that GCG exhibited better hypoglycemic and antioxidant efficacy than EGCG. However, the efficacy and molecular mechanisms of GCG in the protection of DN are unknown. In this study, db/db mice were administered with EGCG or GCG orally for 20 weeks to comparatively investigate their effects on DN. These results revealed that GCG was significantly more effective than EGCG in decreasing water intake and urine excretion, reducing fasting blood glucose levels and systolic blood pressure, improving mesenteric artery contractility, enhancing the right renal hemodynamics, and improving key renal function markers. Through transcriptome analysis, S100A8/S100A9, two regulators of interstitial fibrosis, were identified and found to be more sensitive to GCG intervention, which was further confirmed by mRNA and protein expression data. In addition, the molecular docking analysis results demonstrated that GCG displayed a superior binding affinity toward S100A8/S100A9 in comparison to EGCG. Overall, our study found that GCG holds significant potential for the treatment of DN and outperforms EGCG in terms of efficacy.
Diabetes mellitus is a chronic metabolic disease characterized by insufficient insulin production or action, resulting in impaired blood glucose regulation. Insulin therapy remains critical for managing diabetes; however, it is conventionally administered through regular subcutaneous injections. This invasive route is associated with pain, discomfort, and complications, imposes significant physical and psychological burdens on patients, and adversely affects long‐term adherence. As the global prevalence of diabetes continues to increase, the development of alternative insulin delivery methods has become increasingly urgent. Oral insulin delivery offers a promising alternative by mimicking endogenous insulin secretion via the hepatic portal pathway. However, this approach has significant gastrointestinal barriers, such as enzymatic degradation, variable pH, and low permeability, which can delay effective absorption. Recent advances in nanotechnology have emerged as transformative approaches to overcome these challenges, leveraging advanced nanomaterials for insulin protection, enhanced absorption, and targeted delivery. The present review critically evaluates the recent advancements in nanomaterials used for oral insulin delivery, focusing on GI barriers and highlighting key preclinical and clinical developments.